| NCT03368170 |
Efficacy and Tolerability of IRL790 in Parkinson’s Disease Dyskinesia |
https://ClinicalTrials.gov/show/NCT03368170 |
Completed |
Integrative Research Laboratories AB |
2019-06-12 |
| NCT03319485 |
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT03319485 |
Active, not recruiting |
InSightec |
2021-01-31 |
| NCT03270189 |
Effect of the Visual Information Change in Functional Dystonia |
https://ClinicalTrials.gov/show/NCT03270189 |
Recruiting |
Fondation Ophtalmologique Adolphe de Rothschild |
2021-10-31 |
| NCT03252444 |
Therapeutic Approaches for Subjects With Scapula Dyskinesis |
https://ClinicalTrials.gov/show/NCT03252444 |
Completed |
National Taiwan University Hospital |
2017-05-21 |
| NCT03176771 |
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT03176771 |
Active, not recruiting |
Mitsubishi Tanabe Pharma Corporation |
2020-09-30 |
| NCT03120650 |
Scalp Acupuncture for Dyskinesia After Ischemic Stroke |
https://ClinicalTrials.gov/show/NCT03120650 |
Recruiting |
Shanghai University of Traditional Chinese Medicine |
2020-09-20 |
| NCT02871778 |
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia |
https://ClinicalTrials.gov/show/NCT02871778 |
Completed |
Parion Sciences |
2018-11-20 |
| NCT02799381 |
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson’s Disease (DYSCOVER) |
https://ClinicalTrials.gov/show/NCT02799381 |
Completed |
AbbVie |
2019-09-19 |
| NCT02736955 |
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT02736955 |
Completed |
Neurocrine Biosciences |
2017-06-30 |
| NCT02657681 |
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS) |
https://ClinicalTrials.gov/show/NCT02657681 |
Completed |
Fundación de investigación HM |
2018-09-30 |
| NCT02589340 |
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia |
https://ClinicalTrials.gov/show/NCT02589340 |
Active, not recruiting |
Oregon Health and Science University |
2020-12-31 |
| NCT02198794 |
Reducing Involuntary Movements in Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT02198794 |
Active, not recruiting |
Teva Pharmaceutical Industries |
2020-12-31 |
| NCT03704207 |
Utility of PCD Diagnostics to Improve Clinical Care |
https://ClinicalTrials.gov/show/NCT03704207 |
Recruiting |
Vanderbilt University Medical Center |
2020-06-01 |
| NCT02439203 |
Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia |
https://ClinicalTrials.gov/show/NCT02439203 |
Completed |
Bukwang Pharmaceutical |
2015-12-31 |
| NCT02291861 |
Addressing Involuntary Movements in Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT02291861 |
Completed |
Teva Pharmaceutical Industries |
2016-08-19 |
| NCT02274766 |
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia |
https://ClinicalTrials.gov/show/NCT02274766 |
Completed |
Adamas Pharmaceuticals, Inc. |
2016-03-10 |
| NCT02274558 |
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT02274558 |
Completed |
Neurocrine Biosciences |
2015-09-30 |
| NCT02252380 |
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders |
https://ClinicalTrials.gov/show/NCT02252380 |
Active, not recruiting |
InSightec |
2021-12-31 |
| NCT02195700 |
Aim to Reduce Movements in Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT02195700 |
Completed |
Teva Pharmaceutical Industries |
2015-05-31 |
| NCT02136914 |
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) |
https://ClinicalTrials.gov/show/NCT02136914 |
Completed |
Adamas Pharmaceuticals, Inc. |
2015-12-31 |
| NCT02064010 |
A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT02064010 |
Completed |
Synchroneuron Inc. |
2015-01-31 |
| NCT03813238 |
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents |
https://ClinicalTrials.gov/show/NCT03813238 |
Recruiting |
Teva Pharmaceutical Industries |
2021-09-27 |
| NCT03354455 |
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT03354455 |
Completed |
Danish Research Centre for Magnetic Resonance |
2018-09-16 |
| NCT02003248 |
A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT02003248 |
Completed |
Yonsei University |
2017-05-16 |
| NCT01937078 |
Famotidine for Levodopa-induced Dyskinesia in PD |
https://ClinicalTrials.gov/show/NCT01937078 |
Completed |
University Health Network, Toronto |
2014-03-31 |
| NCT01804920 |
D-Serine Treatment For Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT01804920 |
Active, not recruiting |
Herzog Hospital |
2019-01-31 |
| NCT01767129 |
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson’s Disease Patients |
https://ClinicalTrials.gov/show/NCT01767129 |
Completed |
Avanir Pharmaceuticals |
2015-02-28 |
| NCT01733121 |
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT01733121 |
Completed |
Neurocrine Biosciences |
2013-12-31 |
| NCT01688037 |
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) |
https://ClinicalTrials.gov/show/NCT01688037 |
Completed |
Neurocrine Biosciences |
2013-09-30 |
| NCT01568840 |
Global Postural Reeducation and Segmental Exercises in Patients With Scapular Dyskinesis and Cervicalgia |
https://ClinicalTrials.gov/show/NCT01568840 |
Completed |
Irmandade da Santa Casa de Misericordia de Sao Paulo |
2011-01-31 |
| NCT01563913 |
Reducing Dyskinesia in Parkinson’s Disease With Omega-3 Fatty Acids |
https://ClinicalTrials.gov/show/NCT01563913 |
Completed |
VA Office of Research and Development |
2016-06-30 |
| NCT01543321 |
Xenazine in Late Dyskinetic Syndrome With Neuroleptics |
https://ClinicalTrials.gov/show/NCT01543321 |
Completed |
Centre Hospitalier Universitaire, Amiens |
2017-05-18 |
| NCT01491932 |
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias |
https://ClinicalTrials.gov/show/NCT01491932 |
Completed |
Novartis |
2013-10-31 |
| NCT01491529 |
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias |
https://ClinicalTrials.gov/show/NCT01491529 |
Completed |
Novartis |
2013-04-30 |
| NCT01474421 |
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT01474421 |
Completed |
Novartis |
2013-02-21 |
| NCT01397422 |
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) |
https://ClinicalTrials.gov/show/NCT01397422 |
Completed |
Adamas Pharmaceuticals, Inc. |
2013-05-31 |
| NCT01391390 |
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia |
https://ClinicalTrials.gov/show/NCT01391390 |
Completed |
Beijing HuiLongGuan Hospital |
2011-04-30 |
| NCT01336088 |
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT01336088 |
Completed |
Addex Pharma S.A. |
2012-02-29 |
| NCT04222777 |
Cervical Spine Motion in the Elderly |
https://ClinicalTrials.gov/show/NCT04222777 |
Recruiting |
Zuyderland Medisch Centrum |
2020-03-01 |
| NCT04173845 |
Double Randomized and Placebo Controlled Trail of Tianqi Pingchan Granule to Prevent Levodopa-Induced Dyskinesia |
https://ClinicalTrials.gov/show/NCT04173845 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-12-31 |
| NCT04173832 |
Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine |
https://ClinicalTrials.gov/show/NCT04173832 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-12-31 |
| NCT04086160 |
Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset |
https://ClinicalTrials.gov/show/NCT04086160 |
Enrolling by invitation |
The Hong Kong Polytechnic University |
2020-12-31 |
| NCT03956979 |
A Study in Parkinson’s Disease in paTients With mOderate to seveRe dyskInesiA |
https://ClinicalTrials.gov/show/NCT03956979 |
Recruiting |
Bukwang Pharmaceutical |
2021-06-30 |
| NCT03922711 |
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT03922711 |
Recruiting |
Prilenia |
2020-04-30 |
| NCT03891862 |
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT03891862 |
Recruiting |
Neurocrine Biosciences |
2020-09-30 |
| NCT03832491 |
Effect of Game Based Approach on Oxygenation, Functional Capacity and Quality of Life in Primary Ciliary Dyskinesia |
https://ClinicalTrials.gov/show/NCT03832491 |
Recruiting |
Hacettepe University |
2020-03-15 |
| NCT03698331 |
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine |
https://ClinicalTrials.gov/show/NCT03698331 |
Completed |
Neurocrine Biosciences |
2019-04-03 |
| NCT03531060 |
A Clinical Study of IRL790 in Patients With Parkinson’s Disease Experiencing Levodopa Induced Dyskinesia |
https://ClinicalTrials.gov/show/NCT03531060 |
Completed |
Integrative Research Laboratories AB |
2017-04-12 |
| NCT03495024 |
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates |
https://ClinicalTrials.gov/show/NCT03495024 |
Recruiting |
Corporal Michael J. Crescenz VA Medical Center |
2020-04-30 |
| NCT01267188 |
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT01267188 |
Completed |
Neurocrine Biosciences |
2011-03-31 |
| NCT01173731 |
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias |
https://ClinicalTrials.gov/show/NCT01173731 |
Completed |
Novartis |
2013-10-31 |
| NCT01172379 |
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson’s Disease Patients With “Wearing Off” Motor Fluctuations and “On” Period Dyskinesias |
https://ClinicalTrials.gov/show/NCT01172379 |
Completed |
Eisai Inc. |
2005-02-28 |
| NCT01155115 |
Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia |
https://ClinicalTrials.gov/show/NCT01155115 |
Completed |
The Hospital for Sick Children |
2014-12-31 |
| NCT01113320 |
Safinamide in Levodopa Induced Dyskinesia in Parkinson’s Disease Subjects |
https://ClinicalTrials.gov/show/NCT01113320 |
Completed |
Newron Pharmaceuticals SPA |
2011-11-30 |
| NCT01092065 |
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson’s Disease Patients With Moderate-severe L-dopa Induced Dyskinesia |
https://ClinicalTrials.gov/show/NCT01092065 |
Completed |
Novartis |
2011-07-31 |
| NCT01071395 |
Validation of Dyskinesia Rating Scales |
https://ClinicalTrials.gov/show/NCT01071395 |
Completed |
Rush University Medical Center |
2012-04-30 |
| NCT00986414 |
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT00986414 |
Completed |
Novartis |
2010-12-31 |
| NCT00984100 |
Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy |
https://ClinicalTrials.gov/show/NCT00984100 |
Completed |
Baystate Medical Center |
2015-01-31 |
| NCT00981604 |
Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy |
https://ClinicalTrials.gov/show/NCT00981604 |
Completed |
Children’s Mercy Hospital Kansas City |
2011-08-31 |
| NCT00957918 |
Study of NP002 in Subjects With Idiopathic Parkinson’s Disease to Treat Dyskinesias Due to Levodopa Therapy |
https://ClinicalTrials.gov/show/NCT00957918 |
Completed |
Neuraltus Pharmaceuticals, Inc. |
2010-09-30 |
| NCT00926965 |
Tardive Dyskinesia and Cognitive Function |
https://ClinicalTrials.gov/show/NCT00926965 |
Completed |
Taipei Veterans General Hospital, Taiwan |
2007-12-31 |
| NCT00888186 |
Different Dyskinesias in Parkinson’s Disease and Their Relation to Levodopa Pharmacokinetics |
https://ClinicalTrials.gov/show/NCT00888186 |
Completed |
Uppsala University |
2008-05-31 |
| NCT00888004 |
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson’s Disease Patients |
https://ClinicalTrials.gov/show/NCT00888004 |
Completed |
Novartis |
2009-08-31 |
| NCT00845000 |
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) |
https://ClinicalTrials.gov/show/NCT00845000 |
Completed |
Merck Sharp & Dohme Corp. |
2010-04-30 |
| NCT01393600 |
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder |
https://ClinicalTrials.gov/show/NCT01393600 |
Completed |
Neurocrine Biosciences |
2012-02-29 |
| NCT02405091 |
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT02405091 |
Completed |
Neurocrine Biosciences |
2017-03-31 |
| NCT01385592 |
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias |
https://ClinicalTrials.gov/show/NCT01385592 |
Completed |
Novartis |
2012-09-30 |
| NCT00621998 |
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT00621998 |
Completed |
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan |
2003-12-31 |
| NCT00582673 |
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson’s Disease Patients, and Safety in Combination With L-dopa |
https://ClinicalTrials.gov/show/NCT00582673 |
Completed |
Novartis |
2008-05-31 |
| NCT00406029 |
Dyskinesia in Parkinson’s Disease (Study P04501) |
https://ClinicalTrials.gov/show/NCT00406029 |
Completed |
Merck Sharp & Dohme Corp. |
2008-10-05 |
| NCT00401089 |
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia |
https://ClinicalTrials.gov/show/NCT00401089 |
Completed |
Lawson Health Research Institute |
2006-12-31 |
| NCT00363727 |
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson’s |
https://ClinicalTrials.gov/show/NCT00363727 |
Completed |
GlaxoSmithKline |
2006-01-31 |
| NCT00360568 |
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson’s Subjects |
https://ClinicalTrials.gov/show/NCT00360568 |
Completed |
AbbVie |
2012-10-31 |
| NCT00314288 |
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia |
https://ClinicalTrials.gov/show/NCT00314288 |
Completed |
EMD Serono |
NA |
| NCT00307450 |
Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT00307450 |
Completed |
Technische Universität Dresden |
2009-03-31 |
| NCT00291213 |
Levetiracetam Treatment of Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT00291213 |
Completed |
Yale University |
2006-04-30 |
| NCT00255879 |
Movement Disorders Caused by Antipsychotic Drugs in Older Patients |
https://ClinicalTrials.gov/show/NCT00255879 |
Completed |
University of California, San Diego |
2004-08-31 |
| NCT00190008 |
Piracetam for Treatment Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT00190008 |
Completed |
Beersheva Mental Health Center |
NA |
| NCT00175955 |
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT00175955 |
Completed |
UCB Pharma |
2005-12-31 |
| NCT00164242 |
Treatment of Tardive Dyskinesia With Galantamine |
https://ClinicalTrials.gov/show/NCT00164242 |
Completed |
Caroff, Stanley N., M.D. |
NA |
| NCT00160576 |
Levetiracetam Treatment in Adult Subjects With Parkinson’s Disease Experiencing Troublesome Dyskinesias |
https://ClinicalTrials.gov/show/NCT00160576 |
Completed |
UCB Pharma |
2004-11-30 |
| NCT00114595 |
Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT00114595 |
Completed |
University of Stellenbosch |
NA |
| NCT00105521 |
Sarizotan in Participants With Parkinson’s Disease Suffering From Treatment Associated Dyskinesia |
https://ClinicalTrials.gov/show/NCT00105521 |
Completed |
EMD Serono |
2006-03-31 |
| NCT00105508 |
Sarizotan HC1 in Patients With Parkinson’s Disease Suffering From Treatment-associated Dyskinesia |
https://ClinicalTrials.gov/show/NCT00105508 |
Completed |
EMD Serono |
2006-02-28 |
| NCT00086294 |
ACP-103 to Treat Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT00086294 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00076674 |
Levetiracetam Treatment of L-dopa Induced Dyskinesias |
https://ClinicalTrials.gov/show/NCT00076674 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00004576 |
Study of LY300164 for the Treatment of Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT00004576 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00036296 |
Effects of Talampanel on Patients With Advanced Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT00036296 |
Completed |
Teva Pharmaceutical Industries |
2007-02-28 |
| NCT00672373 |
Extract of Ginkgo Biloba and Tardive Dyskinesia |
https://ClinicalTrials.gov/show/NCT00672373 |
Completed |
Beijing HuiLongGuan Hospital |
2007-05-31 |